November 29, 2021
Article
Investigators have developed an antibody-based treatment for Alzheimer disease, as well as a protein-based vaccine.
November 26, 2021
Video
Ron Aung-Din, MD, the clinical medical advisor of Pyscheceutical, and Chad Harman, the CEO of Pyscheceutical, discuss a novel approach for administering psychedelics for the treatment of brain disorders that does not induce hallucinogenic effects.
Podcast
Diagnosis, treatment options, and the role of the pharmacist in patient care are all important factors when looking at multiple sclerosis as a whole.
November 25, 2021
Ocrelizumab is indicated for the treatment of relapsing forms of multiple sclerosis, including clinically isolated syndrome, relapsing-remitting MS, and active secondary progressive disease, in adults.
November 23, 2021
Investigators from Michigan Medicine analyzed data from 16,700 individuals in a new study.
November 22, 2021
Tosymra is indicated for the acute treatment of migraine with or without aura in adults.
November 19, 2021
The guidance updates the recommendations on dopaminergic medications that were published in 2002 on the initiation treatment for Parkinson disease.
Approximately 40% of patients with stage IV melanoma have brain metastases at diagnosis.
November 18, 2021
Aducanumab-avwa is a human, immunoglobulin gamma 1 (IgG1) monoclonal antibody directed against aggregated soluble and insoluble forms of amyloid beta.
November 12, 2021
Patients were randomized 1:1 to receive either erenumab or topiramate, with the erenumab arm split into dosages of 70 mg or 140 mg.
